Unlocking a new potential in diabetes care by combining a natural flavonoid with a first-line antidiabetic medication.

Diabetes mellitus, particularly type 2 diabetes (T2DM), is a chronic metabolic disorder affecting millions worldwide. Characterized by high blood sugar levels due to insulin resistance or insufficient insulin production, T2DM poses significant health risks if not properly managed. Complications can range from cardiovascular diseases like heart attack and stroke to microvascular issues such as kidney failure and neuropathy.

Current treatments often focus on controlling blood glucose levels, but many medications come with side effects like hypoglycemia (dangerously low blood sugar levels), gastrointestinal discomfort, and sometimes even adverse impacts on liver and kidney functions. Moreover, the rising prevalence of diabetes calls for more effective and affordable therapies.

Recent research has turned towards natural compounds and their potential synergistic effects when combined with existing medications. One such compound is quercetin, a flavonoid found in many fruits and vegetables. When combined with metformin, a widely prescribed antidiabetic drug, quercetin may offer enhanced benefits in managing diabetes and its complications.

Understanding Quercetin

Quercetin is a plant pigment (flavonoid) that gives many fruits, vegetables, and flowers their rich colors. It’s abundant in foods like apples, onions, berries, and tea. Known for its antioxidant and anti-inflammatory properties, quercetin has been studied for various health benefits, including heart health, immune support, and now, blood sugar regulation. Quercetin is also an over the counter supplement that may prove useful to combine with metformin

Key Properties of Quercetin:

• Antioxidant Effects: Neutralizes harmful free radicals that can damage cells.
• Anti-inflammatory Actions: Reduces inflammation, which is linked to many chronic diseases.
• Blood Sugar Regulation: May improve insulin sensitivity and reduce blood glucose levels.

The Role of Metformin in Diabetes

Metformin is often the first medication prescribed for T2DM. It helps lower blood sugar levels by:

• Reducing Glucose Production: Decreases the amount of sugar produced by the liver.
• Improving Insulin Sensitivity: Helps the body’s cells respond better to insulin.
• Enhancing Glucose Uptake: Increases sugar absorption by muscle cells.

While effective, metformin can cause side effects like gastrointestinal discomfort and, in rare cases, lactic acidosis (a buildup of lactic acid in the body).

The Study: Exploring the Synergy of Quercetin and Metformin

Purpose: To investigate whether combining quercetin with metformin enhances the antidiabetic effects and reverses complications like endothelial dysfunction (damage to the lining of blood vessels) in diabetic rats.

Methodology Overview:

• Subjects: 75 male Sprague Dawley rats.
• Inducing Diabetes: Diabetes was induced using streptozotocin (STZ) and nicotinamide. STZ damages insulin-producing cells in the pancreas, mimicking T2DM.
• Grouping: Rats were divided into five groups:
  1. Normal Control: Healthy rats with no treatment.
  2. Diabetic Control: Diabetic rats with no treatment.
  3. Quercetin Treatment: Diabetic rats treated with quercetin.
  4. Metformin Treatment: Diabetic rats treated with metformin.
  5. Combination Treatment: Diabetic rats treated with both quercetin and metformin.

Dosages and Duration:

• Quercetin: Administered orally at 10 mg per kilogram of body weight daily.
• Metformin: Administered orally at 180 mg per kilogram of body weight daily.
• Treatment Period: 30 consecutive days.

Measurements Taken:

• Blood Glucose Levels: Fasting blood sugar measured before and after treatment.
• Liver and Kidney Function Tests: Levels of enzymes like ALT, AST, and creatinine to assess organ health.
• Lipid Profile: Levels of triglycerides, cholesterol, LDL (bad cholesterol), and HDL (good cholesterol).
• Vascular Function Tests: Studying the aorta’s ability to relax and contract.
• Histological Examination: Microscopic analysis of liver, kidney, pancreas, and aorta tissues.
• Molecular Markers: Assessing proteins related to blood vessel health, such as eNOS and VCAM-1.

Key Findings

Blood Glucose Reduction:

• Significant Decrease: The combination therapy reduced fasting blood glucose levels more effectively than either treatment alone.
• Numbers to Note: Diabetic rats had blood glucose levels around 18 mmol/L (a unit of concentration). After combination treatment, levels dropped to approximately 7 mmol/L, nearing the normal control levels of about 6 mmol/L.

Improved Lipid Profile:

• Lower Bad Fats: Triglycerides and LDL cholesterol levels decreased significantly with combination therapy.
• Higher Good Cholesterol: HDL cholesterol levels increased, which is beneficial for heart health.

Liver and Kidney Function:

• Reduced Enzyme Levels: ALT and AST levels, which indicate liver damage when elevated, decreased in the combination group.
• Creatinine Levels: An indicator of kidney function, creatinine levels were lower in the combination group, suggesting better kidney health.

Vascular Health Improvements:

• Enhanced Endothelial Function: Blood vessels in treated rats responded better, indicating healthier vessel function.
• Relaxation Responses: The aorta’s ability to relax (important for blood pressure regulation) was improved in the combination group.

Histological Observations:

• Liver and Kidney Tissues: Showed less damage and more normal structures in the combination group.
• Pancreatic Islets: The areas producing insulin were better preserved.
• Aorta: Less fatty deposition and structural damage, suggesting reduced atherosclerosis risk.

Molecular Markers:

• eNOS (Endothelial Nitric Oxide Synthase): Increased levels promote blood vessel relaxation and health.
• VCAM-1 (Vascular Cell Adhesion Molecule-1): Decreased levels reduce inflammation and plaque formation in arteries.

Statistical Significance Explained:

• P-Values: A statistical measure indicating the probability that the results are due to chance.
• Understanding the Numbers: A p-value less than 0.05 (p < 0.05) suggests that there’s less than a 5% probability the results are random, indicating strong evidence that the treatment made a real difference.

Discussion: What Do These Findings Mean?

Synergistic Effect:

• Better Together: Quercetin and metformin work more effectively when combined, enhancing each other’s antidiabetic properties.
• Multiple Pathways: While metformin primarily reduces glucose production in the liver, quercetin may improve insulin secretion and protect pancreatic cells.

Mechanisms Behind the Benefits:

• Antioxidant Action: Quercetin reduces oxidative stress, which damages cells and tissues.
• Anti-inflammatory Effects: Both compounds reduce inflammation, a key factor in diabetes complications.
• Endothelial Function: Improved blood vessel health reduces the risk of cardiovascular diseases.

Potential for Human Application:

• Translating to Humans: While this study was in rats, the results are promising for potential human benefits.
• Natural and Accessible: Quercetin is widely available in foods and supplements, making it an accessible adjunct therapy.

Disclaimer: This article is for informational purposes only and does not substitute professional medical advice. Always consult a qualified healthcare provider for guidance tailored to your health situation.

At CanadianInsulin.com, we’re dedicated to providing up-to-date information and quality medications to support your health needs. Explore our range of GLP-1 receptor agonists and consult with our pharmacists for more information.